Completed PHASE4 INTERVENTIONAL 2-arm NCT02145611

Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension

12-week Randomized Study to Compare the Effect of Vildagliptin vs. Glibenclamide Associated to Metformin in Endothelial Function in Patients With Type 2 Diabetes and Hypertension

Sponsor: Dr. José Fernando Vilela-Martin MD PhD

Conditions Endothelial Dysfunction Hypertension Type 2 Diabetes Mellitus

Interventions Glibenclamide Vildagliptin

Updated 5 times since 2017 Last updated: Aug 15, 2016 Started: Jul 31, 2013 Primary completion: May 31, 2016 Completion: May 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02145611, this PHASE4 trial focuses on Endothelial Dysfunction and Hypertension and remains completed. Sponsored by Dr. José Fernando Vilela-Martin MD PhD, it has been updated 5 times since 2013, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dr. José Fernando Vilela-Martin MD PhD
Novartis

Data source: Hospital de Base

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• São José do Rio Preto, Brazil